Effect of Interleukin-6 Receptor Inhibition in Patients With Ischemic Stroke Undergoing Endovascular Treatment

Sponsor
Suzhou Municipal Hospital of Anhui Province
Study ID
NCT06238024
Phase
PHASE2/PHASE3
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 80 Years
Healthy Volunteers
Not accepted

Interventions

  • Tocilizumab — DRUG
    Single dose intravenous application
  • NaCl 0.9% 100ml — DRUG
    Single dose intravenous application

Study Details

Tocilizumab may exert neuroprotective effects in patients with ischemic stroke undergoing endovascular treatment

Key Dates

Start date
Feb 2, 2024
Status verified
Jul 2024
Primary completion
Jun 25, 2024
Completion
Sep 22, 2024

Study Design

Enrollment
108 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Tocilizumab group
    Intravenously for more than 1 hour.
  • Placebo Comparator: Control group
    Intravenously for more than 1 hour.

Primary Outcome Measure

Change from baseline in infarct-core volume [ Time Frame: 72 hours ]

Related Studies